Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.
Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.
Bolt Biotherapeutics, Inc. presented new preclinical data at the 2021 SITC Annual Meeting, highlighting the potential of its Boltbody™ ISAC candidates for cancer treatment. Key presentations included BDC-2034, targeting CEA, which showed promising tumor clearance and immune activation in CEA-expressing cancers. Additional data on a PD-L1-targeted ISAC demonstrated improved anti-tumor efficacy. The company also validated Dectin-2 as a novel target for reprogramming tumor-associated macrophages. Bolt aims to initiate clinical development of BDC-2034 in 2022.
Bolt Biotherapeutics (BOLT) reported Q3 2021 financial results, revealing a cash position of $290.5 million, expected to fund operations through 2023. The company is making progress in its BDC-1001 Phase 1/2 trial for HER2-expressing solid tumors, with interim data from over 50 patients to be presented at the ESMO Immuno-Oncology Congress in December. Collaboration revenue reached $0.8 million, while R&D expenses increased to $19.3 million. The loss from operations for Q3 was $23.5 million, compared to $12.4 million in the same period last year.
Bolt Biotherapeutics (Nasdaq: BOLT) announced that CEO Randall C. Schatzman, Ph.D., will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 1:00 p.m. PT. The event includes a fireside chat and opportunities for investor meetings. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event. Bolt is focused on developing innovative immuno-oncology agents, particularly its lead candidate BDC-1001, targeting HER2-expressing solid tumors.
Bolt Biotherapeutics (Nasdaq: BOLT) announced three presentations at the 2021 SITC Annual Meeting in Washington, D.C., from Nov. 10-14. These presentations focus on assets in Bolt’s preclinical pipeline, featuring two immune-stimulating antibody conjugate (ISAC) candidates and an agonist antibody. The poster presentations will include:
- BDC-2034: CEA-targeting ISAC for solid tumors.
- Dectin-2: Aiming at tumor macrophage reprogramming.
- PD-L1-targeted ISAC: Enhancing anti-tumor efficacy in preclinical models.
Bolt Biotherapeutics (Nasdaq: BOLT) announced a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate the combination of BDC-1001, a HER2-targeting immune-stimulating antibody conjugate, with Bristol's PD-1 inhibitor, Opdivo (nivolumab). The Phase 1/2 trial will explore safety and effectiveness in HER2-expressing solid tumors. Preliminary data presented at ASCO indicated promising results. Bristol will supply Opdivo for the trial, which is set to begin dose escalation later in 2021.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company, has announced their participation in four virtual investor conferences this September. Key events include presentations at the Citi’s 16th Annual BioPharma Virtual Conference on Sept. 8, the Wells Fargo Virtual Healthcare Conference on Sept. 9, a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Sept. 13, and a presentation at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Sept. 30. Live and archived webcasts will be available on Bolt's website.
Bolt Biotherapeutics (BOLT) has entered into a collaboration with Innovent Biologics to develop three new anti-cancer therapeutic immune-stimulating antibody conjugates (ISACs). Innovent will pay an upfront fee of $5 million and handle development costs through clinical proof of concept. The partnership allows Innovent exclusive rights in Greater China while Bolt retains rights elsewhere. Potential future equity investments could reach $10 million, alongside milestone payments and royalties based on product development and commercialization.
Bolt Biotherapeutics (NASDAQ: BOLT) announced promising updates in its Phase 1/2 trial for BDC-1001 targeting HER2-expressing solid tumors, with data expected in 2H 2021. The company reported a robust cash position of $310.9 million as of June 30, 2021, which will fund operations through 2023. A collaboration with Genmab aims to develop bispecific ISACs for cancer treatment, securing an upfront payment of $10 million and potential future earnings of $285 million per program. R&D expenses rose to $19.7 million, while G&A expenses increased to $4.1 million in Q2 2021.
Bolt Biotherapeutics (BOLT) has showcased positive preliminary data from a Phase 1/2 clinical trial of BDC-1001 at the ASCO Annual Meeting. As of January 29, 2021, 20 patients treated with the HER2-targeting ISAC displayed tolerable safety with no serious adverse effects. Clinical activity included stable disease and a confirmed partial response in some patients. The trial aims to enroll up to 390 patients, with further results expected in H2 2021, including monotherapy and combination treatments.
Genmab and Bolt Biotherapeutics announced a collaboration aimed at developing novel cancer therapies using Genmab's antibody technologies and Bolt's immune-stimulating antibody conjugate (ISAC) platform. The partnership includes an upfront payment of USD 10 million and an equity investment of USD 15 million from Genmab. They plan to develop multiple bispecific ISAC candidates, with Genmab holding options to commercialize up to three candidates. Total potential milestone payments could reach USD 285 million per candidate, depending on successful development and commercialization.